Aggregometer Market Size, Share Global Analysis Report, , 2020 – 2026

Industry Insights

[189+ Pages Report] The worldwide demand (consumption) for the Aggregometer market was estimated at about USD 360 Million in 2019 and is anticipated to register a revenue of around USD 570 Million by end of 2026, growing at a CAGR of around 6.7% between 2020 and 2026.

Market Overview

The aggregometer, also known as a platelet aggregation method, is a device that has been used to determine the function of platelets since the twentieth century. Platelets play an important role in blood coagulation and wound healing, which is accomplished by a mechanism called platelet aggregation. Platelets are thought to play a part in thrombotic, vascular ischemic, and hemorrhagic disorders. As a result, anti-platelet therapy (APT) is considered the gold standard for many coronary disorders, prompting the creation of new anti-platelet medications as well as a variety of tests to assess platelet function. Platelets, also known as thrombocytes, are a type of cell found in our bodies that aid in the prevention of excessive bleeding caused by internal or external injuries. Platelets aid in blood coagulation, avoiding blood loss, and are thus one of the body's most essential cells. The platelet aggregometer is used to keep track of platelet function.

Industry Growth Factors

The rising burden of chronic diseases, the growing geriatric population, and technological advances in platelet aggregometer are all contributing to the growth of the platelet aggregation devices industry. The platelet aggregometer market is expected to rise due to the rising prevalence of platelet dysfunctioning diseases. The platelet aggregometer market is expected to expand due to increased research around rare diseases such as Bernard-Soulier Disease (BSS) and Glanzmann Thrombasthenia (GT) around the world using the platelet aggregometer. While platelet aggregometry is a time-consuming method, the results obtained using a platelet aggregometer are more accurate and stable, and as a result, it is widely used for laboratory evaluation, which is expected to drive the platelet aggregometer market. It also aids in the evaluation of platelet function, i.e. aiding in the process of preventing bleeding, and minor variations in platelet function may have a negative impact on a person's health who is already suffering from an acute illness. The prevalence of platelet-related disorders is often high in chronic disease as well as in patients with dietary nutrition abnormalities, which leads to the evaluation of normal platelet function and count, which is necessary for normal function, which is expected to drive the platelet aggregometer market.

The global burden of cardiac mortality is rising due to an increase in the occurrence of heart attacks such as stroke and coronary heart disease, which has fueled the growth of the platelet aggregation devices industry. Cardiovascular disease, for example, is identified as the underlying cause of death in the American Heart Association Research Report 2018, accounting for nearly 836,546 deaths in the United States. Platelet aggregation devices, which are used to diagnose bleeding disorders, are expected to see an increase in demand as the prevalence of bleeding disorders rises. Immune thrombocytopenia was projected to be 4 per 100,000 in children and 3 per 100,000 in adults worldwide in 2020, according to data presented by Genetic Home Reference.

Segmentation Analysis

The market for aggregometer is divided into three categories: form, application, and end-use. The market is classified into flow cytometry, impedance whole blood aggregometry, lumi-aggregometry, light transmission aggregometry (LTA), and others based on the product form. Among these, LTA is the gold standard method for determining platelet function. LTA is the most commonly used screening technique for excessive platelet activity and antiplatelet therapy management. The market is divided into analysis and clinical applications based on the application. Since the aggregometer has been the most widely used equipment in clinical laboratories as a strong analytical instrument for decades, the clinical applications segment is expected to hold the largest market share. It can be used to determine the inhibitory and excitatory effects of drugs on platelets, as well as to evaluate the effectiveness of antiplatelet therapy drugs in humans. It's also used in in vitro studies to evaluate platelet production in human samples before clinical trials. The total range of systems in an aggregometer is equal to the number of individual measurements that can be run at the same time. The total range of systems in an aggregometer is equal to the number of individual measurements that can be run at the same time.

Regional Analysis

Due to the higher number of procedures performed in the region, North America is expected to dominate the global platelet aggregometer market in terms of revenue. Due to the higher adoption of the platelet aggregometer in the area for various test evaluations, Europe is projected to be the second most lucrative market. The platelet aggregometer market in Latin America is expected to develop steadily over the forecast period, owing to the platelet aggregometer's growing adoption. With rapidly rising product penetration, Asia-Pacific is expected to be the fastest-growing market. Because of the low acceptance of the product and low test volume in the field, MEA is the least profitable platelet aggregometer sector.

Report Scope

Competitive Players

The major players dominating the global aggregometer market in terms of revenue and development are:

• Bio/Data Corporation
• Chronolog Corporation
• Helena Laboratories
• Perfusion
• Hart Biologicals
• Alpha Laboratories
• Instrumentation Laboratory
• Biola
• WerfenLife
• S.A.F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Tem Group
• Sysmex Corporation
• Haemonetics Corporation
• Drucker Diagnostics
• and Others.

These key players in order to obtain a reputed position in the global market have implemented several strategies such as signing agreements, bonds, contracts, partnerships, joint ventures, new product launches, collaborations, and mergers & acquisitions.

COVID-19 Analysis

Due to the higher number of procedures performed in the region, North America is expected to dominate the global platelet aggregometer market in terms of revenue. Due to the higher adoption of the platelet aggregometer in the area for various test evaluations, Europe is projected to be the second most lucrative market. However, growing evidence of COVID 19's impact on platelet aggregation has led to an increase in research studies on the process.

By Type Segmentation Analysis:

• Flow-Cytometry
• Impedance Whole Blood Aggregometry
• Lumi-Aggregometry
• Light Transmission Aggregometry (LTA)
• Others

By Application Segmentation Analysis

• Research Applications
• Clinical Applications

By End-Use Segmentation Analysis

• Research and Academic Institutes
• Standalone Hospitals
• Blood Banks
• Diagnostic Laboratories
• Others

Regional Segment Analysis

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• The Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of MEA